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Abstract: Background: The development of therapeutic vaccines requires thorough knowledge of
potential hazards associated with long-term inactivation of self-proteins. Among potential targets,
interleukin 13 (IL-13) merits consideration, as monoclonal antibodies disrupting IL-13 signaling are
proving to be exceedingly effective in common conditions such as atopic dermatitis. Objective: Given
the mass publication of scientific data, an appraisal of safety aspects is challenging. Methods: We
here provide a three-fold approach to survey clinically relevant information on off-target effects, both
adverse and beneficial, that may potentially be encountered in patients undergoing long-term IL-13
inactivation. First, we review non-clinical data in vivo and in vitro. Second, we summarize safety
data accumulating from patients dosed with anti-IL-13 drugs. Third, we exploit human mutation data
as well as emerging large-scale genetic datasets (global exome data from 60,000 patients) to obtain
information on any association of IL-13-inactivating genetic variants with disease states. In addition,
we: (1) dissect the precise efficacy signals obtained with various drugs targeting IL-13 and/or IL-4,
and (2) summarize unintended, but potentially beneficial effects of prolonged IL-13 inactivation on
several functional systems. Results: Prolonged repression of IL-13 in several thousand patients so far
has not uncovered any non-redundant functions of IL-13 in immune defense. Furthermore, missense
mutations in the key genes IL-13, IL-13Rα1, IL-13Rα2, IL-4, IL-4Rα are common, while no case reports
have been published on any immune deficiency or increased risk of neoplastic disease associated
with such mutations, suggesting that these genes do not harbor non-redundant roles in adult outbred
humans. In terms of efficacy, data from clinically used drugs strongly suggest that targeting IL-13 only,
as opposed to IL-13 and IL-4, may be effective in eczema while being more selective. Importantly,
several lines of evidence suggest that inhibition of IL-13 may in fact harbor potentially beneficial
effects on non-targeted systems, including glucose metabolism, hepatic fibrosis, and atherosclerosis,
suggesting that respective outcomes should be systematically captured in patients dosed with IL-13
interfering drugs. Collectively, available evidence suggests that IL-13 may fulfill safety requirements
required for the target of a therapeutic vaccine.
Keywords: vaccine; VLP; IL-13; drug safety; IL-4; atopic dermatitis; asthma
1. Introduction
The selective inhibition of cytokine function via monoclonal antibodies has revolutionized the
treatment of chronic inflammatory conditions. Despite their phenomenal success, there are some
limitations to these drugs, including excessive cost for health care providers, emergence of anti-drug
antibodies, and the need for relatively frequent dosing, requiring logistics for shipment and storage of
sensitive biological products. Therapeutic vaccines eliciting an endogenous antibody response against
cytokines provide a potential solution to overcome these shortcomings.
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Aside from the question of efficacy, however, the main concern in the use of vaccines, as well as
biologic drugs, is the safety of long-term elimination of self-proteins. Thus, blocking of TNF-α may
predispose toward opportunistic infections (recently reviewed in [1]). Similarly, elimination of IL-6
requires prior immunization against hepatitis B to avoid infection [2].
The safety of long-term elimination of a given protein is determined by its non-redundant roles.
In order to assess these in a systematic fashion for IL-13, the present review will consider mutually
complementary data. First, non-clinical data generated in vitro and in animal models will be reviewed.
Obviously, an in-depth review of all IL-13-related data is not intended here. Rather, the focus will be on
any toxicity/safety-related findings. The importance of non-clinical data is two-fold. On the one hand,
they allow prediction of expected safety hazards in clinical settings, thereby informing monitoring.
On the other hand, if the clinical data, as is often the case, does not bear out limiting adverse effects
that could have been expected based on non-clinical data, this supports the notion that for a given
postulated biological function, the target in question (here IL-13) is indeed redundant.
The second, and in many ways most informative, data set consists of safety data accumulating
in the clinical use of monoclonal antibodies. In this context, three IL-13-targeting drugs are
being developed in addition to the IL-4/IL-13 dual-specific drug dupilumab which has already
been approved.
A third data set consists of genetic data. These not only include the traditional reporting of
human pedigrees or sporadic mutants associated with clinical phenotypes, but also screens for
over-representation of IL-13 blocking mutations in infectious diseases, as well as global databases
cataloguing frequent mutations that have failed to emerge as associated with clinical phenotypes. If
inactivating mutations are found to be of high frequency, then their non-association with disease states
represents an informative negative finding.
Finally, this review will summarize data suggesting that blocking IL-13 may harbor unintended
but potentially beneficial effects based on non-clinical data. The purpose here is to highlight that
systematic and targeted monitoring of such data in patients undergoing IL-13 blocking antibody
treatment is essential and required to gauge the clinical relevance of these data.
2. Non-Clinical Data on IL-13 and Susceptibility to Disease
The present review section is based on a PubMed search using the strategy: (IL-13/ IL-13R/
Interleukin-13/ Interleukin-13 receptor AND ‘infection’) in: abstract/title; cut-off 10 October 2018.
By way of limitation, this review is not intended to be exhaustive but rather attempts to focus on data
bearing a predictive value on disease susceptibility in humans.
2.1. Schistosoma and Helminth Susceptibility
A wealth of literature is available examining the possibility of increased susceptibility to
Schistosoma infection. One group of clinically relevant data are studies of associations of human
polymorphisms with disease. Thus, an IL-13 promoter variant (−1111T/C) was found to confer
slightly increased susceptibly to Schistosoma infection (T/T genotype protective); however, effects of
age, gender, and village (the latter likely reflecting variable genetic background) were in fact found to be
many orders of magnitude higher [3]. A study on a Brazilian population found a suggestive protective
association of the same promoter allele as well as a non-conserved functional allele (rs20541→ R130Q)
against Schistosoma mansoni [4]. A French study found association of the same IL-13 variant (rs1800925)
and Schistosoma infection [5]. Another study did not find association of Schistosoma infection and IL-13
but only IL-5 polymorphisms [6]. Studies with genetically altered inbred mice indicate that survival in
Schistosoma infection is not impaired in IL-13 deficient mice [7] and that granuloma formation is only
impaired in combined IL-4/IL-13 ablation [8]. In fact, ablation of IL-13 ameliorates lung fibrosis in
this setting (see below on this aspect). A recent review of intestinal helminth infection also showed
redundancy between IL-4 and IL-13, indicating that IL-13 deficiency can be compensated for by IL-4 in
murine models of infection [9]. Taken together, despite the available data suggesting a role for IL-13 in
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the containment of infections such as intestinal nematodes [10], no evidence has been found by genetic
association or patients that deficiency in IL-13 affects susceptibility or disease severity or natural course
in humans in Schistosoma infection. Nonetheless, mouse data on inbred strains do suggest that an
absence of IL-13 might negatively impact the defense against intestinal parasites [11], suggesting that
caution may nevertheless be prudent.
2.2. Leishmaniasis
Cutaneous Leishmaniasis (CL) is the most common type of Leishmania infection causing large
ulcers on exposed parts of the body. IL-13 is believed to be responsible for non-healing progressing
cutaneous disease, previously demonstrated on wild type, IL-13−/−, IL-4Rα−/− and IL-4−/− mice that
encountered Leishmania major and Leishmania mexicana [12–14]. IL-4Rα−/− mice were fully resistant to
L. mexicana, however IL-4−/− mice developed persistent lesions following disease progression [13].
IL-13−/− and IL-4Rα−/− groups developed lesions similar to wild type upon initial infection.
However, those cleared, and the mice recovered, indicating that IL-4 is the prevailing cytokine
responsible for further susceptibility. The resistant phenotype was highly improved in double knockout
mice for IL-13 and IL-4 in L. major infection [14]. A possible explanation for why IL-13−/− mice became
resistant to the parasites is that IL-13 is suppressing the functions of interferon-gamma (IFN-γ) and
IL-12, which play key roles in clearance as shown in previous investigations, indicating susceptible
phenotypes upon their modulation [15–18]. Thus, an IL-13 vaccine could supress parasite progression
to a chronic non-healing state and enhance T helper 1 (Th1) responses, allowing recovery. Certainly, no
data exist to suggest that an IL-13 vaccine would exacerbate susceptibility to Leishmania.
2.3. Viral Infections
Regarding a potential effect of blocking IL-13 on viral infections, available evidence from clinical
studies with IL-13 blocking antibodies has so far failed to provide any data suggesting clinically
relevant impact. Non-clinical studies have shown that Th2 cytokines, including IL-13, may in
fact impair immunity to rhinoviruses or respiratory syncytial virus (RSV) either directly [19–21]
or indirectly via signal transducer and activator of transcription 6 (STAT6) activation [22] and a
recent review [19] summarizes evidence suggesting that blocking IL-33/IL-13 may be beneficial
in the treatment of virus-associated lung disease. These viral infections in childhood can leave
individuals vulnerable to development of chronic inflammatory diseases in adult life and result
in impaired antiviral responses [23–25]. For instance, a study of influenza A virus shows that
transcriptionally active remnants of the virus can remain in lung cells once infection has cleared
and can also contribute to chronic lung disease partially accounted for by IL-13 expression [25].
This susceptibility was proposed to be a cause of increased IL-13 signaling via STAT6 [25]. Severe
influenza infection can be observed in people suffering from asthma, which leads to further chronic
disease exacerbations post viral infection [26]. Furthermore, there is a link between rhinovirus infection,
elevated IL-13 levels and contributions of asthma [27]. Asthmatic children had reduced IFN-β and
IFN-λ production in comparison to healthy subjects during rhinovirus (RS-16) encounter, leading to
disease exacerbations [28]. Similarly, another study of RS-16 illustrated that IL-4 and IL-13 impaired
production of IFN-β and IFN-λ and inhibited toll-like receptor 3 (TLR3) and interferon regulatory
transcription factor 3 (IRF3), thus allowing the virus to replicate [23]. It has also been suggested that
IL-13 is involved in mucus metaplasia that can increase susceptibility to rhinovirus [29] and decreasing
IL-13 levels can reduce mucus production, airway hyperresponsiveness and partly reduce airway
eosinophilia during rhinoviral infection [30]. Contribution to asthma exacerbations are also the case for
RSV as IL-13 is believed to be a mediator of viral pathogenesis driving pulmonary eosinophilia via the
IL-33/ST2 pathway [19,31,32]. IL-13-expressing natural killer cells are found to be a source for airway
inflammation [33] and were significantly increased during RSV infection [32]. Furthermore, there is a
genetic association between a haplotype at the IL-13-IL-4 gene locus and increased IL-13 production
with a correlation in elevated risk of RSV bronchiolitis in childhood [34]. RSV can therefore manifest
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and significantly worsen asthmatic exacerbations by driving airway inflammation and tissue damage
during infection [31]. IL-13 overexpression may also be a susceptibility factor for viral respiratory
infection, especially in those suffering from an ongoing chronic inflammatory disease. Collectively,
these studies suggest that Th2 cytokines can have a negative impact on antiviral responses and
can contribute to future health complications. Taken together, therefore, available data suggest that
therapeutic targeting of IL-13 can relieve chronic inflammatory disease and possibly provide better
protection during respiratory infections.
2.4. Other Infections
High levels of IL-13 (> 10 pg/mL) in respiratory secretions were found to predispose to
life-threatening rhinovirus infection in children younger than two years in a large national survey (n
= 56,560) from Argentina, suggesting that blocking IL-13 in this setting may in fact be beneficial [27].
Despite a targeted search, a study from China found associations between IL-4 but not IL-13
polymorphisms and coal miners’ pneumoconiosis [35]. Chlamydia commonly cause infections of
the respiratory and genital tract. IL-13 increases susceptibility to infection as well as severity by driving
increased inflammation and bacterial manifestation [36]. Conversely, respiratory Chlamydia infection
in early life was shown to reduce IL-13Rα2 expression and attenuate IL-13 production with potential
secondary benefit later in life on asthma susceptibility [37].
2.5. Septic Shock
A Spanish study on 48 children with sepsis found significantly lower IL-13 levels in patients six
hours after onset of refractory shock [38], while a British study in 31 adults observed a correlation of
TNF-α and IL-13 levels and a high level of each with septic shock [39]. As of the cut-off date of this
review, there is no PubMed available evidence indicating that IL-13 deficiency has serious effects on
specific susceptibility to infectious agents and/or septic shock.
2.6. Malignancies
While in vitro studies on IL-13 in various cancer model systems are abundant, no clinical or in vivo
mouse data link IL-13 directly to pro-tumor or anti-tumor effects to date. Noteworthy are studies
linking IL-13 to cancer-associated fibrosis in Hodgkin’s lymphoma and pancreatic cancer [40–43], tying
in with a general pro-fibrotic effect of IL-13 (discussed below). Also, the abundance of IL-13Rα2 on
glioblastoma cells was clinically explored by designing an IL-13-linked toxin to kill tumor cells in a
phase I clinical trial [44]. There are data on IL-13 promoter polymorphisms as well as IL-13 serum
levels in a variety of cancer entities of various stages, but no clear causality patterns have emerged to
date. Emerging data from IL-13 blocking clinical trials so far confirm the absence of notable effects on
cancer development (see below). However, confidence in the safety of vaccine-based IL-13 blocking
will necessarily be increased upon the absence of safety signals in widespread and prolonged clinical
dosing with anti-IL-13 drugs in patients.
3. Safety Signals from Clinical Trials and Post-Marketing Surveillance
Dupilumab, a dual-acting drug blocking both IL-4 and IL-13 function (Figure 1b) was approved
by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2017 for
use in atopic dermatitis. Approval for use in asthma is expected for Q4 2018. Recent phase III [45]
(n = 210), [46] (n = 1908) studies on asthma showed no significant and/or severe treatment emergent
infections. The same was previously found in published studies on atopic dermatitis [47] (n = 325), [48]
(n = 1379). No long-term safety concerns have emerged either as part of the Regeneron Open Label
Extension (OLE) study, featuring continuous dosing for a total of three years (n = 2000, latest update
2017, REGN668/SAR231893, [49]), nor through post-marketing safety monitoring eighteen months
after market introduction in the US. These data are reassuring in terms of safety and are reflected in
a recent meta-analysis that identifies conjunctivitis as the only adverse effect emerging from present
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data [50]. It is worth remembering, however, that patients with a history of helminth infection were
excluded from clinical trials.
Currently available safety data for the IL-13 selective monoclonal antibodies confirm the
dupilumab data. Thus, for tralokinumab, collectively sizeable phase II populations are available
including [51] (n = 79), [52] (n = 409), [53] (n = 452), [54] (n = 194), as well as for lebrikizumab,
including [55] (n = 1081), [56] (n = 313), and [57] (n = 209). A further anti-IL-13 monoclonal,
anrukinzumab, studied in active ulcerative colitis (n = 84) also found no significant adverse effects [58].
This study also measured and detected feedback elevation of IL-13 in peripheral blood of treated
patients. Overall, available clinical data from patients dosed with anti-IL-4/IL-13 drugs have not
uncovered safety signals to date that would suggest a vaccine approach to be unsafe, as reflected in a
recent independent meta-review of these data [59].
4. Evidence for IL13 Related Phenotypes from Large-Scale Genetic Databases
The advent of high-throughput genome wide sequencing has provided several databases
compiling phenotypes linked to genetic polymorphisms and/or mutations. In the case of IL-13, a search
in the Single Nucleotide Polymorphism Database (dbSNP) for IL-13, IL-13Rα1 and IL-13Rα2 reveals
no clinically-relevant phenotype-associated variants. There are data linking IL-13 polymorphisms with
the outcome of children with minimal change nephrotic syndrome [60,61], although the significance of
this remains uncertain. Furthermore, there are no published pedigrees and / or single patient case
reports involving variants mapping to the above listed genes, nor entries listed on Online Mendelian
Inhertience in Man (OMIM).
The completion of the Exome Aggregation Consortium (ExAC) sequencing of 60,000 genomes
from a variety of global populations has enabled a quantitative assessment of the impact of genetic
variants on overall fitness in terms of evolutionary selection. We extracted these data for key genes
related to IL-13 signaling. As shown in Table 1, non-conserved and even loss-of-function mutations are
frequent. Except for IL-13Rα1 (numbers set in bold), none of the genes exhibit apparent evolutionary
selection against homozygous occurrence of loss-of-function mutations. Although the high z-score
could suggest that IL-13Rα1 may be important in pre-natal development, IL-13Rα1-deficient mice
in fact exhibit normal fertility rates and display no global development abnormality but only a
specific defect in M2-type macrophage development [62]. Furthermore, the Exome Variant Server
(EVS) compiles allele frequencies for approximately 6000 genomes from European and African
ancestries, respectively. We extracted EVS-listed variants for IL-13 relevant genes with high probability
of deleterious function based on: (1) non-conserved amino-acid replacement, (2) high probability
(score > 0.8) in PolyPhem2-based prediction, and (3) 100% conservation of the main allele between
humans and chimpanzee (Table 2). These data show that deleterious variants in these genes are, in
fact, surprisingly common, in some cases amounting to 25% of all minor variants identified (Table 2,
printed in bold). Therefore, the absence of clinical case studies reporting health issues in individuals
harboring any of these mutations in the public space is significant, suggesting that deficient IL-13
signaling caused by congenital mutations is not associated with severe immunodeficiency or failure
to thrive.
Table 1. Global counter-selection against mutations in key genes affecting interleukin 13
(IL-13) signaling. 1
Gene Type ofMutation Expected (n)
2 Observed (n) 2 Metric (z/pLI) 3
IL-13
Synonymous 25.9 26 −0.01
Missense 48.4 50 −0.11
LoF 5.4 3 0.03
IL-13Rα1
Synonymous 33.5 25 0.91
Missense 79.2 80 −0.04
LoF 11.6 0 0.98
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Table 1. Cont.
Gene Type ofMutation Expected (n)
2 Observed (n) 2 Metric (z/pLI) 3
IL-13Rα2
Synonymous 33.3 30 0.35
Missense 77.8 72 0.32
LoF 12.0 8 0.00
IL-4Rα
Synonymous 138.2 146 −0.41
Missense 283.0 296 −0.38
LoF 23.0 7 0.03
IL-4
Synonymous 29.7 29 0.08
Missense 57.3 49 0.54
LoF 6.0 2 0.17
1 Data shown were extracted from the ExAC tool [63] and represent a total of approximately 60,000 genotypes.
Half of these are derived from Caucasian samples, the remainder from African/Latino/East Asian, Finnish, South
Asian, and Other, respectively (for details, see ExAC website); 2 Expected and observed numbers are calculated
based on exon number and gene length (for details, see EXAC); 3 z scores and “probability of intolerance” (pLI) (for
loss-of-function (LoF) express a degree of deviation between expected and observed. The closer the score is to 1, the
greater the discrepancy (for details, see EXAC website). Negative scores indicated that observed variants are even
more frequent than expected.
Table 2. Frequencies of damaging variants in key genes affecting IL-13 signaling. 1
Gene MAF European 2 MAF African 2 Change rs ID 3
IL-13
0.000 0.023 P60L rs146770163
0.023 0.000 W68R rs143660447
0.047 0.000 L72P rs148077750
0.023 0.000 V87G rs199513811
0.000 0.023 T96N rs374668631
0.000 0.114 V125M rs140196099
IL-4
0.000 0.023 R109W rs373334025
0.023 0.000 A118V rs149950065
0.000 0.023 K150M rs149147538
IL-4R
0.012 0.000 S6C rs151179009
0.000 0.273 V85M rs141983833
0.000 0.023 P169L rs145473866
0.000 0.023 R200W rs370524692
IL-13Rα1
0.000 0.026 S153R rs368784033
0.000 0.052 N157K rs138018049
0.119 0.000 R340C rs139927088
0.000 0.261 H398Y rs145848479
0.000 0.157 D403N rs149035999
0.000 0.026 D414N rs142037578
IL-13Rα2
0.000 0.052 R343C rs375241228
0.000 0.026 R248W rs369836103
0.000 0.026 T107M rs368005707
0.000 0.026 R74Q rs377163094
0.000 0.026 P55L rs370152207
1 Data shown were extracted from the Exome Variant Server [64] using the following filters: probability of
protein-damaging function >0.8 (PolyPhen2 score); non-conserved protein amino acid replacement; conservation in
major allele between Human and Chimpanzee genomes; 2 Minor allele frequencies (MAF) for European and African
descent populations, respectively where MAF is a percentage among all minor alleles in multi-allelic variants (for
details, see EVS website); 3 rsID is the dbSNP reference for SNP identifier (for details, see EVS website). Data set in
bold print represent MAF > 0.1 in at least one population.
5. IL-13 on Its Own Represents a More Selective Target Than IL-4/IL-13 in Combination for
Treatment of Atopic Conditions
Several drugs targeting IL-13 are undergoing clinical development or already marketed.
The precise efficacy, as well as adverse effect profile of each drug is related to its molecular mode of
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action. As shown in Figure 1a, IL-13 and IL-4 signal through partially overlapping pathways. Both
cytokines will activate the so-called type-2 IL-4 receptor, followed by JAK2/Tyk2 phosphorylation
and subsequent STAT translocation. By contrast, only IL-4 activates the type-1 IL-4 receptor, whereas
IL-13 additionally binds to IL-13α2, commonly regarded as an inhibitory decoy receptor. By binding to
IL-4Rα, dupilumab essentially abrogates signaling through both IL-4 and IL-13 (Figure 1b). In contrast,
pascolizumab directly binds to IL-4, thereby preserving type-2 receptor activation via IL-13 (Figure 1c).
This drug did not show clinical efficacy, thereby suggesting that the effect of this system on asthma and
eczema pathogenesis primarily proceeds through the IL-4 type 2 receptor [65]. Finally, IL-13 selective
antibodies (Figure 1d) prevent IL-13 binding but preserve the activation of both active receptor systems.
The emerging clinical efficacy of these drugs both in asthma and atopic eczema suggests that the
more selective inactivation of IL-13 achieves sufficient activity while preserving IL-4 activity, with a
potentially important gain in safety profile in terms of immunity to infectious agents [9]. A number of
selective as well as global JAK inhibitors are currently also being developed for atopic disease [66],
as well as other conditions including cancer. However, the complex nature of precise JAK/STAT
coupling of IL-4, as well as other signal transducing pathways [67], prevent an unambiguous mapping
of specific adverse effects and/or activity profiles to relative IL-4/IL-13 signaling.
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6. Additional Potential Effects of an IL-13 Vaccine
When considering the potential of IL-13 as a vaccine target to improve atopic disease, potential
off-target effects in addition to those considered above may occur which, although unintended, may in
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fact prove of interest for further vaccine applications. Therefore, this final section will summarize data
suggesting potential vaccine effects on specific functional systems that warrant dedicated monitoring
during clinical applications based on currently available data.
6.1. Improvement of Fibrosis
A substantial amount of data indicates that an anti-IL-13 vaccine may be beneficial for the
prevention of the amelioration of hepatic fibrosis in Schistosoma infection [68] as well as non-infectious
fibrosis, as reported in many studies (see above) [69–71]. A preventative effect in this regard could
indeed constitute a major independent indication for anti-IL-13 vaccination.
6.2. Glucose Metabolism
Blocking IL-13 signaling may in fact improve impairment in glucose metabolism [72–74] and
regulate glucose uptake and pathways involved in skeletal muscle maintenance [75,76]. Conversely,
however, IL-13 has also been suggested to fulfill an autocrine anti-inflammatory role in diabetes [77].
6.3. Atherosclerosis
A somewhat related activity of IL-13, also possibly involving macrophage activation, is regulation
of atherosclerosis, where the precise role and mechanism and its clinical significance remain to
be elucidated [75]. Animal models of IL-13 deficiency suggest IL-13 may act as a contributor in
atherosclerosis [78–80]. Other studies suggest that IL-13 leads to atherosclerosis by inducing expression
of peroxisome proliferator activated receptor δ (PPARδ) or PPARβ in the adipose tissue and by
increasing CD36 levels [81,82]. However, obviously atherosclerosis development is multifactorial
and complex. Furthermore, the Th1 and Th2 responses contribute differently during various stages
of plaque development, and IL-13 alone cannot reverse disease progression [83,84]. Clearly, a more
systematic monitoring of glucose metabolism, as well as markers of systemic inflammation in patients
currently dosed with anti-IL-13 drugs, would be important to better understand the clinical significance
of the available non-clinical data in this regard.
7. Conclusions
The clinical use of dupilumab, as well as selective anti-IL-13 drugs, has shown that blocking
IL-13 is effective both for the treatment of asthma and atopic dermatitis and may be of use in other
atopic conditions (e.g., severe contact allergy). A precise understanding of the molecular signaling
mechanisms suggests that targeting IL-13, while equally effective, preserves IL-4 signaling through the
type-2 IL-4 receptor which may constitute an important safety benefit regarding immunity, especially
to helminth infections. A large body of genomic data appear to confirm emerging safety data from
anti-IL-13/IL-4 clinical use that prolonged blocking of IL-13 is not associated with reduced systemic
immunity or opportunistic infections. Notably, it remains to be seen whether the pro-fibrotic activity
of IL-13 is of clinically high enough relevance to render a vaccination treatment effective in several
conditions involving increased fibrosis (e.g. hepatic fibrosis, pulmonary fibrosis due to various
etiologies). Finally, the clinical use of IL-13 drugs should be utilized to specifically monitor the effects
of IL-13 blocking on glucose metabolism.
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